May 04, 2023 8:30am EDT Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
May 03, 2023 8:30am EDT Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
Apr 20, 2023 6:45am EDT Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
Apr 19, 2023 8:30am EDT Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
Apr 11, 2023 8:30am EDT Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
Apr 04, 2023 8:30am EDT Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
Mar 02, 2023 4:01pm EST Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
